A
web-based Atlas of Patient-Derived Xenografts
of cancer patients:A resource of MURAL PDX data
Download csv
Download xlsx
This table displays an overview of the database
The table can be sorted by any field, simply by clicking on the column header
The table can be sorted by any field, simply by clicking on the column header
| PDX ID | Sample Site | Sample Source | Age Sample Collected | PSA at diagnosis (ng/mL) | Id | Sample ID | Current PDX Generation | Average PDX Generation Time (days ± SEM) | Tumor preparation2 | Pubmed ID | Created Date | Audit Date | Patient Id | Gleason Score | Primary Gleason Score | Secondary Gleason Score | Grade Group | Tumour Grade | D'Amico Risk Classification | Primary Tumour Volume (cc) | Treatment Prior to Specimen Collection | PDX Host Type | PDX Graft Site |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 407M Cx | Liver | Biopsy | 80 | NA | 46 | 407M | 9 (5*) | 128 ± 30 | Tumor solid | 34413304 | 01/05/2022 11 a.m. | 13/05/2024 1 a.m. | 407 | — | — | — | — | — | — | 0.0 | ADT, docetaxel, abiraterone, enzalutamide | Castrate | Subcutaneous |
| 410.51A | Right lung sub pleural tumour | Autopsy | 71 | 30 | 47 | 410.51A | 11 | 60 ± 7 | Tumor solid | 34413304 | 01/05/2022 11 a.m. | 13/05/2024 1 a.m. | 410 | — | — | — | — | — | — | 0.0 | ADT, docetaxel, cabazitaxel, abiraterone, enzalutamide | Testosterone supplemented | Subcutaneous |
| 410.51A Cx | Right lung sub pleural tumour | Autopsy | 71 | 30 | 48 | 410.51A | 10 (6*) | 108 ± 9 | Tumor solid | 34413304 | 01/05/2022 11 a.m. | 13/05/2024 1 a.m. | 410 | — | — | — | — | — | — | 0.0 | ADT, docetaxel, cabazitaxel, abiraterone, enzalutamide | Castrate | Subcutaneous |
| 422M | Brain | Surgery | 72 | NA | 49 | 422M | 11 | 62 ± 4 | Tumor solid | 34413304 | 01/05/2022 11 a.m. | 13/05/2024 1 a.m. | 422 | — | — | — | — | — | — | 0.0 | ADT, docetaxel, cabazitaxel, abiraterone, enzalutamide | Testosterone supplemented | Subcutaneous |
| 422M Cx | Brain | Surgery | 72 | NA | 50 | 422M | 7 (2*) | 184 ± 72 | Tumor solid | 34413304 | 01/05/2022 11 a.m. | 13/05/2024 1 a.m. | 422 | — | — | — | — | — | — | 0.0 | ADT, docetaxel, cabazitaxel, abiraterone, enzalutamide | Castrate | Subcutaneous |
| 424M | Lymph node | Biopsy | 76 | NA | 51 | 424M | 6 | 136 ± 38 | Tumor solid | 34413304 | 01/05/2022 11 a.m. | 13/05/2024 1 a.m. | 424 | — | — | — | — | — | — | 0.0 | ADT, zoladex and cosudex | Testosterone supplemented | Subcutaneous |
| 435.1A | Right temporal fossa | Autopsy | 68 | 16.2 | 52 | 435.1A | 5 | 51 ± 3 | Tumor solid | 34413304 | 01/05/2022 11 a.m. | 13/05/2024 1 a.m. | 435 | — | — | — | — | — | — | 0.0 | ADT, carboplatin plus etoposide | Testosterone supplemented | Subcutaneous |
| 435.1A Cx | Right temporal fossa | Autopsy | 68 | 16.2 | 53 | 435.1A | 17 (13*) | 56 ± 2 | Tumor solid | 34413304 | 01/05/2022 11 a.m. | 13/05/2024 1 a.m. | 435 | — | — | — | — | — | — | 0.0 | ADT, carboplatin plus etoposide | Castrate | Subcutaneous |